Monoclonal antibody · Antagonist of CTLA-4 · developed by Adagene
Firastotug is a human monoclonal antibody that binds CTLA-4 on T cells and blocks its inhibitory signaling, enhancing cytotoxic T-lymphocyte-mediated immune responses against cancer cells. It is being studied in advanced and metastatic solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04501276 | Phase 1 | Advanced/Metastatic Solid Tumors | Completed | ADAG |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced/Metastatic Solid Tumors
Updated Oct 3, 2026. Something wrong or missing? Report it on the ADAG page.
See ADAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ADAG catalysts and pipeline →